Mount Sinai Showcases Hematology Research at the 67th ASH Annual Meeting
Scientists and physicians from the Icahn School of Medicine at Mount Sinai will present new findings in blood cancers, sickle cell disease, and other hematologic disorders at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, Saturday through Tuesday, December 6–9.
ASH is the world’s largest gathering of experts in blood diseases, and this year’s meeting will highlight major advances in diagnosis, treatment, and patient care. Mount Sinai researchers will deliver both oral and poster presentations revealing innovative science and emerging clinical insights.
This press release lists some of Mount Sinai’s contributions to this year’s annual meeting:
Oral Presentations:
Recent insights into the pathophysiology of hematologic disease with fetal origins
Elvin Wagenblast, PhD
Saturday, December 6, 4:40-5 pm EST
https://submit.hematology.org/program/presentation/670410
Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study
Shambavi Richard, MD
Saturday, December 6, 3 pm EST
https://submit.hematology.org/program/presentation/675741
https://meetings-api.hematology.org/api/abstract/vmpreview/299964
Travel distance to treatment center does not independently impact survival in Acute Myeloid Leukemia (AML): A national cancer database (NCDB) analysis
Douglas Tremblay, MD
Saturday, December 6, 3 pm EST
https://meetings-api.hematology.org/api/abstract/vmpreview/297886
Real-world treatment patterns and outcomes in patients with myelofibrosis who presented with thrombocytopenia and anemia at initiation of pacritinib treatment
Douglas Tremblay, MD
Sunday, December 7, 5:30 pm EST
https://meetings-api.hematology.org/api/abstract/vmpreview/295899
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
John Mascarenhas, MD
Sunday, December 7, 10:15-10:30 am EST
https://submit.hematology.org/program/presentation/680685
https://meetings-api.hematology.org/api/abstract/vmpreview/290259
Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials
Douglas Tremblay, MD
Monday, December 8, 2:45 pm EST
https://meetings-api.hematology.org/api/abstract/vmpreview/290539
S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.
Adolfo Aleman, PhD
Monday, December 8, 3:30 pm EST
https://submit.hematology.org/program/presentation/678483
https://meetings-api.hematology.org/api/abstract/vmpreview/302828
Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients
Douglas Tremblay, MD
Monday, December 8, 5:45 pm EST
https://meetings-api.hematology.org/api/abstract/vmpreview/291228
TET2 mutations drive cell-autonomous type I interferon production and selective advantage through TRIM4 silencing
Baosen Jia, PhD (Lab of Eirini Papapetrou, MD, PhD)
https://meetings-api.hematology.org/api/abstract/vmpreview/301317
Poster Presentations:
Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis
John Mascarenhas, MD
https://submit.hematology.org/program/presentation/675789
https://meetings-api.hematology.org/api/abstract/vmpreview/296767
Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial
John Mascarenhas, MD
https://submit.hematology.org/program/presentation/674486
https://meetings-api.hematology.org/api/abstract/vmpreview/296869
Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A
John Mascarenhas, MD
https://submit.hematology.org/program/presentation/680622
https://meetings-api.hematology.org/api/abstract/vmpreview/298987
Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population
Joshua Brody, MD
https://submit.hematology.org/program/presentation/676757
https://meetings-api.hematology.org/api/abstract/vmpreview/291440
Identifying epigenetic vulnerabilities for treatment of HMA refractory myeloid leukemia
Alan Shih, MD, PhD
https://meetings-api.hematology.org/api/abstract/vmpreview/292485
Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm
Graham Wehmeyer, MD; Adam Kittai,MD
https://meetings-api.hematology.org/api/abstract/vmpreview/298191
Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL –
Graham Wehmeyer, MD; Adam Kittai, MD; Thomas Marron, MD, PhD; Joshua Brody, MD
https://meetings-api.hematology.org/api/abstract/vmpreview/298207
Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy
Alessandro Lagana, PhD
https://meetings-api.hematology.org/api/abstract/vmpreview/302583
Epigenetic targeting of SETD8 in multiple myeloma
Rudra Prasad Dutta, PhD; Samir Parekh, MBBS
https://meetings-api.hematology.org/api/abstract/vmpreview/300758
Prolonged cytopenias after BCMA CAR-T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity
Sundar Jagannath, MBBS
https://meetings-api.hematology.org/api/abstract/vmpreview/291522
Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers
Tarek Mouhieddine, MD; Sundar Jagannath, MBBS
https://meetings-api.hematology.org/api/abstract/vmpreview/298681
Seasonal variation in chronic and acute pain in patients with sickle cell disease
Galia Pollock, MD
https://submit.hematology.org/program/presentation/678865
https://meetings-api.hematology.org/api/abstract/vmpreview/303134
Interim analysis of a placebo controlled study of dronabinol for adults with sickle cell disease and chronic pain
Susanna Curtis, MD, PhD
https://submit.hematology.org/program/presentation/678874
https://meetings-api.hematology.org/api/abstract/vmpreview/303642
Grade I acute graft-vs-host disease: Treat or not?
James Ferrara, MD
https://meetings-api.hematology.org/api/abstract/vmpreview/297400
To see a full list of the presentations and posters and to learn more about the 67th American Society of Hematology annual meeting, visit https://www.hematology.org/meetings/annual-meeting
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.